Chord Therapeutics: New oral treatments for NMOSD & myasthenia gravis
Founder Arthur Roach and CEO Tom Plitz introduce Chord Therapeutics’ mission to bring new oral treatments to patients with rare diseases. Chord Therapeutics launches with USD 16 million Series A investment from Omega Funds.
Chord Therapeutics is a clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMO) and myasthenia gravis (MG).